These include the use of different T-cell subsets, enhancement of in vivo persistence of adoptively transferred T cells and induction of endogenous T-cell responses to multiple or mutated tumour epitopes.26, 28, 29, 30, 31 Lymphodepleting chemotherapy or total body irradiation are often used together with systemic IL-2 administration to enhance engraftment, survival and antitumour reactivity of the adoptively transferred T cells. The gene discussed is IL2; the disease is neoplasm.